These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 10976785)
1. Endothelin receptor antagonists: current status and perspectives. Clozel M J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S65-68. PubMed ID: 10976785 [TBL] [Abstract][Full Text] [Related]
2. Endothelin antagonism with bosentan: a review of potential applications. Roux S; Breu V; Ertel SI; Clozel M J Mol Med (Berl); 1999 Apr; 77(4):364-76. PubMed ID: 10353441 [TBL] [Abstract][Full Text] [Related]
3. Endothelin antagonism with bosentan: current status and future perspectives. Ono K; Matsumori A Cardiovasc Drug Rev; 2002; 20(1):1-18. PubMed ID: 12070530 [TBL] [Abstract][Full Text] [Related]
4. Bosentan and the endothelin system in congestive heart failure. Ellahham SH; Charlon V; Abassi Z; Calis KA; Choucair WK Clin Cardiol; 2000 Nov; 23(11):803-7. PubMed ID: 11097125 [TBL] [Abstract][Full Text] [Related]
5. Rationale and perspective of endothelin-1 antagonism in acute heart failure. Kiowski W; Suetsch G; Oechslin E; Schalcher C; Brunner-Larocca HP; Bertel O J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S53-7. PubMed ID: 11811379 [TBL] [Abstract][Full Text] [Related]
7. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? Spieker LE; Noll G; Ruschitzka FT; Lüscher TF J Am Coll Cardiol; 2001 May; 37(6):1493-505. PubMed ID: 11345356 [TBL] [Abstract][Full Text] [Related]
8. [Pulmonary arterial hypertension. Therapy with the endothelin-1 receptor antagonist bosentan]. Musch A Med Monatsschr Pharm; 2006 Jul; 29(7):242-5. PubMed ID: 16866076 [TBL] [Abstract][Full Text] [Related]
9. [The pharmacology of endothelin and its antagonist bosentan]. Clozel M; Roux S Ann Endocrinol (Paris); 2000 Feb; 61(1):75-9. PubMed ID: 10790596 [TBL] [Abstract][Full Text] [Related]
15. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Kalra PR; Moon JC; Coats AJ Int J Cardiol; 2002 Oct; 85(2-3):195-7. PubMed ID: 12208583 [TBL] [Abstract][Full Text] [Related]
16. Endothelin and heart failure. Nambi P; Clozel M; Feuerstein G Heart Fail Rev; 2001 Dec; 6(4):335-40. PubMed ID: 11447308 [TBL] [Abstract][Full Text] [Related]
17. The clinical potential of endothelin receptor antagonists in cardiovascular medicine. Ferro CJ; Webb DJ Drugs; 1996 Jan; 51(1):12-27. PubMed ID: 8741230 [TBL] [Abstract][Full Text] [Related]
18. Hemodynamic effects of bosentan in patients with chronic heart failure. Kiowski W; Sütsch G; Oechslin E; Bertel O Heart Fail Rev; 2001 Dec; 6(4):325-34. PubMed ID: 11447307 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic role of bosentan in hypertension: lessons from the model of perinephritic hypertension. Donckier JE Heart Fail Rev; 2001 Dec; 6(4):253-64. PubMed ID: 11447300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]